gpt ver3.7en :
page2, in "<Preparation of Bacteria>", The name of antibiotic supplied in LB+maltose broth was corrected (from Cm) to Km. YG6020 is Kanamycin resistance, not Chloramfenicol.

gpt ver3.6en :
page2, in "<Titration (Survival)>", The dilution step(1 and 2) was modified from "Add 2 ul of the 20-fold diluted suspension" to "Add 10 ul of the 100-fold diluted suspension". Dilution Factor is not changed.

gpt ver3.6ja :
page4, "（２）Titer(Survival)の測定" で、サンプルの希釈法について「20倍希釈したpackaged sampleを2μl加え」→「100倍希釈したpackaged sampleを10μl加え」に変更。実質的な希釈率は変わらない。

Spi^- assay ver2.0en :
MgSO₄ is added to TOP and BOTTOM agar plates (final canc. 10 mM) to improve plaque formation.
In the spot test for confirmation, three strains are used (XL-1Blue MRA, XL-1Blue MRA(P2) and WL95(P2)). Spi^- mutant has Red^-/Gam^- mutation. But Some types of Gam^- mutant may also make plaque on the XL-1Blue MRA(P2) plate. By using another P2 lysogen, WL95(P2), Red^-/Gam^- mutants can be selected.

Spi- ver1.4en :
After in vitro packaging reactions, each packaged phage sample is adjusted to the final volume of 300 ul with SM buffer.
For the titration, 2 plates/sample are used (Dilution Factor = 3000).
For the selection, 2 plates/sample are used (300 ul = 150 ul x 2 plates).

spi ver1.3en :
page2, in "Titration of the Packaged Phage with Strain XL-1 Blue MRA", Some comments were added. (See below)

[ Titer = Number of plaques (average of 2 plates) × Dilution Factor ]
;Dilution Factor = 5000

spi ver1.2en :
page2, in "Titration of the Packaged Phage with Strain XL-1 Blue MRA", The dilution step(1 and 2) was modified from "Add 2 ul of the 20-fold diluted suspension" to "Add 10 ul of the 100-fold diluted suspension". Dilution Factor is not changed.